Sign Up Today and Learn More About CRISPR Therapeutics Stock
Invest in or calculate the value of your shares in CRISPR Therapeutics or other pre-IPO companies through EquityZen's platform.
CRISPR Therapeutics Stock
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.
About CRISPR Therapeutics Stock
Founded
2013
Headquarters
Cambridge, MA, US
Total Funding
127M
Industries
Software, Artificial Intelligence, Data and Analytics
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.
CRISPR Therapeutics Press Mentions
Stay in the know about the latest news on CRISPR Therapeutics
New Data From First Human Crispr Trials Shows Promising Results
Forbes • Nov 19, 2019
Hospital in China denies links to world’s first gene-edited babies
TechCrunch • Nov 26, 2018
UPDATED: CRISPR scientist in China claims his team’s research has resulted in the world’s first gene-edited babies
TechCrunch • Nov 25, 2018
Most Active Stock to Track: CRISPR Therapeutics AG (CRSP)
Nasdaq Place (press release) • Jun 26, 2018
Form 4 CRISPR Therapeutics AG For: Jun 15 Filed by: Kulkarni Samarth
StreetInsider.com • Jun 16, 2018
CRISPR Therapeutics Management
Leadership team at CRISPR Therapeutics
Scientific Founders
Daniel Anderson
Scientific Founders
Emmanuelle Charpentier
Join now and verify your accreditation status to gain access to:
- CRISPR Therapeutics current valuation
- CRISPR Therapeutics stock price
- Available deals in CRISPR Therapeutics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in CRISPR Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like CRISPR Therapeutics through EquityZen funds. These investments are made available by existing CRISPR Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell CRISPR Therapeutics stock?
Shareholders can sell their CRISPR Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 320K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
